2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10019A
    Varenicline dihydrochloride 866823-63-4 98.85%
    Varenicline (CP 526555-18) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation.
    Varenicline dihydrochloride
  • HY-107867
    (±)-Clopidogrel bisulfate 135046-48-9 99.97%
    (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects.
    (±)-Clopidogrel bisulfate
  • HY-109027
    Cavosonstat 1371587-51-7 99.36%
    Cavosonstat (N91115) is an orally active S-nitrosoglutathione reductase (GSNOR) inhibitor. Cavosonstat is a CFTR stabilizer, and can be used for cystic fibrosis research.
    Cavosonstat
  • HY-111021
    ASP-4058 952565-91-2 99.54%
    ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.
    ASP-4058
  • HY-111409
    RIP1 kinase inhibitor 1 2095515-38-9 99.96%
    RIP1 kinase inhibitor 1 (compound 22) is a highly potent, orally available, and brain-penetrating RIP1 kinase inhibitor (pKi=9.04).
    RIP1 kinase inhibitor 1
  • HY-112152
    GSK726701A 945721-87-9 98.27%
    GSK726701A is a novel prostaglandin E2 receptor 4 (EP4) partial agonist with a pEC50 of 7.4.
    GSK726701A
  • HY-119936
    GLPG2451 2055015-61-5 99.68%
    GLPG2451 is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, which effectively potentiates low temperature rescued F508del CFTR with an EC50 of 11.1 nM.
    GLPG2451
  • HY-124768
    PDE12-IN-3 1803357-22-3 98.02%
    PDE12-IN-3 is a phosphodiesterase 12 (PDE12) inhibitor with a pXC50 of 7.68. Antiviral activity.
    PDE12-IN-3
  • HY-128356
    SPL-410 2351886-00-3 99.38%
    SPL-410 is an orally active, highly potent and selective hydroxyethylamine based SPPL2a (Signal Peptide Peptidase Like 2a) inhibitor, with an IC50 of 9 nM.
    SPL-410
  • HY-131967
    CD73-IN-4 2216764-29-1 99.35%
    CD73-IN-4 is a potent and selective methylenephosphonic acid CD73 inhibitor, with an IC50 of 2.6 nM for human CD73. CD73-IN-4 is potential for the research of cancer immunology.
    CD73-IN-4
  • HY-132808
    Atuzabrutinib 1581714-49-9 98.00%
    Atuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of Btk (Bruton's tyrosine kinase) inhibitor. Atuzabrutinib inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling.
    Atuzabrutinib
  • HY-147263
    Dovramilast 340019-69-4 99.66%
    Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (HY-B0329)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB).
    Dovramilast
  • HY-148571
    TP0597850 2642181-22-2 99.09%
    TP0597850 is a selective inhibitor of MMP2 (IC50=0.22 nM). TP0597850 has a long MMP2 dissociation half-life (t1/2=265 min).
    TP0597850
  • HY-153245
    JNJ-64264681 2101524-34-7 98.14%
    JNJ-64264681 is a potent, orally active, selective and irreversible covalent BTK inhibitor. JNJ-64264681 exhibits good pharmacokinetic characteristics and can be used for cancer and autoimmune diseases research.
    JNJ-64264681
  • HY-B0230S
    Phenylbutazone(diphenyl-d10) 1219794-69-0 99.90%
    Phenylbutazone(diphenyl-d10) is the deuterium labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research.
    Phenylbutazone(diphenyl-d10)
  • HY-P99035
    Naptumomab 1412892-09-1 99.90%
    Naptumomab is a fusion protein of a tumor-targeting superantigen (TTS). Naptumomab stimulates the immune system to recognize and kill tumor cells and can be used in the study of refractory solid tumors such as renal cell carcinoma.
    Naptumomab
  • HY-P99327
    Tregalizumab 1207446-68-1
    Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies.
    Tregalizumab
  • HY-P99485
    Brazikumab 1610353-18-8 99.408%
    Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease.
    Brazikumab
  • HY-P99489
    Budigalimab 2098225-93-3 99.79%
    Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors.
    Budigalimab
  • HY-P99490
    Burfiralimab 2460809-80-5
    Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies.
    Burfiralimab
Cat. No. Product Name / Synonyms Application Reactivity